KoBioLabs
고바이오랩 · 348150
Health Care Biotechnology · KOSDAQ
Market cap US$53.3M (₩73.6B)
Overview
KoBioLabs develops drugs that work by modifying the human microbiome, the community of bacteria and other microorganisms that naturally live in the body and influence health.
It is a clinical-stage biotech listed on KOSDAQ, Korea's tech-focused stock exchange, targeting conditions including immune, metabolic, and neurological diseases. The company handles the full drug-development process in-house, from candidate discovery through clinical trials, and has built a proprietary drug-discovery platform called Smartiome, which it is advancing with AI and multi-omics data.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$24M
- FY2024US$49.5M
- FY2025US$50.2M
Operating profit
- FY2023−US$13.4M
- FY2024−US$5M
- FY2025−US$7M
Net income
- FY2023−US$11M
- FY2024−US$3.3M
- FY2025−US$5.1M
Key ratios (FY2025)
Why it matters
KoBioLabs claims to have initiated the first global clinical trials for a microbiome-based drug originating in Korea, covering two functional materials for immune diseases.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?